JP2012518407A - 単離された単球集団及び関連した治療応用 - Google Patents

単離された単球集団及び関連した治療応用 Download PDF

Info

Publication number
JP2012518407A
JP2012518407A JP2011551065A JP2011551065A JP2012518407A JP 2012518407 A JP2012518407 A JP 2012518407A JP 2011551065 A JP2011551065 A JP 2011551065A JP 2011551065 A JP2011551065 A JP 2011551065A JP 2012518407 A JP2012518407 A JP 2012518407A
Authority
JP
Japan
Prior art keywords
cells
isolated
population
monocyte
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011551065A
Other languages
English (en)
Japanese (ja)
Inventor
フリードランダー，マーチン
リツター，マシユー・アール
モレノ，スタシー・ケー
エル−カーレイ，モハンマド・エー
Original Assignee
ザ スクリプス リサーチ インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティチュート filed Critical ザ スクリプス リサーチ インスティチュート
Publication of JP2012518407A publication Critical patent/JP2012518407A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/051—Lipid A (MPA, MPL)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1497—Particle shape

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011551065A 2009-02-20 2010-02-19 単離された単球集団及び関連した治療応用 Withdrawn JP2012518407A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20817309P 2009-02-20 2009-02-20
US61/208,173 2009-02-20
US28324409P 2009-11-30 2009-11-30
US61/283,244 2009-11-30
PCT/US2010/000477 WO2010096177A1 (en) 2009-02-20 2010-02-19 Isolated monocyte populations and related therapeutic applications

Publications (1)

Publication Number Publication Date
JP2012518407A true JP2012518407A (ja) 2012-08-16

Family

ID=42634163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011551065A Withdrawn JP2012518407A (ja) 2009-02-20 2010-02-19 単離された単球集団及び関連した治療応用

Country Status (11)

Country Link
EP (1) EP2398900A4 (ko)
JP (1) JP2012518407A (ko)
KR (1) KR20110123778A (ko)
CN (1) CN102317446A (ko)
AU (1) AU2010216374A1 (ko)
BR (1) BRPI1008392A2 (ko)
CA (1) CA2752679A1 (ko)
EA (1) EA201190109A1 (ko)
MX (1) MX2011008826A (ko)
WO (1) WO2010096177A1 (ko)
ZA (1) ZA201105869B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522830A (ja) * 2013-05-22 2016-08-04 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 眼疾患および眼障害の治療のためのヒト単球亜集団

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101668462B1 (ko) * 2015-02-26 2016-10-24 충북대학교 산학협력단 혈액성분을 유효성분으로 포함하는 녹내장의 예방 또는 치료용 약제학적 조성물
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
CN114441419B (zh) * 2022-01-29 2022-11-22 杭州翔宇医学检验实验室有限公司 流式圈门方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031467A2 (en) * 2002-07-25 2006-03-23 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
EP1718735A1 (en) * 2004-02-11 2006-11-08 Aldagen, Inc. Stem cell populations and methods of use
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
CA2656463C (en) * 2006-06-28 2015-12-01 Yeda Research And Development Co. Ltd. Method of treatment of age-related macular degeneration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522830A (ja) * 2013-05-22 2016-08-04 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 眼疾患および眼障害の治療のためのヒト単球亜集団

Also Published As

Publication number Publication date
BRPI1008392A2 (pt) 2015-08-25
CN102317446A (zh) 2012-01-11
KR20110123778A (ko) 2011-11-15
CA2752679A1 (en) 2010-08-26
WO2010096177A1 (en) 2010-08-26
EP2398900A1 (en) 2011-12-28
AU2010216374A1 (en) 2011-08-18
EP2398900A4 (en) 2012-08-22
ZA201105869B (en) 2012-10-31
EA201190109A1 (ru) 2012-07-30
MX2011008826A (es) 2011-11-02

Similar Documents

Publication Publication Date Title
JP7001575B2 (ja) Ｂ細胞の増加及び評価方法並びに疾患治療のための増加ｂ細胞の使用方法
RU2403906C2 (ru) Способ лечения ретинопатии при недоношенности и родственных ретинопатических заболеваний
RU2331669C2 (ru) Популяция стволовых кроветворных клеток и ее применение
Friedlander et al. Progenitor cells and retinal angiogenesis
JP2020518260A (ja) 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP2018518975A5 (ko)
US20220146534A1 (en) Biomarkers for CNS Disease Modification
TW201130978A (en) Method of isolation of stem cell populations from peripheral blood using sized-based separation (elutriation)
EP1402005B1 (en) A method of purification of cells
WO2023216799A1 (zh) 一种人nkt细胞系及其应用
JP2010509916A (ja) 単離された骨髄球様細胞集団及びそれを用いた治療方法
KR20170010894A (ko) 림프구로부터의 다계열 분화능 세포 생성 방법
JPH08509377A (ja) ヒトのエリスロイド前駆細胞集団
JP2012518407A (ja) 単離された単球集団及び関連した治療応用
JP2008537478A (ja) 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法
US20120009166A1 (en) Isolated monocyte populations and related therapeutic applications
US20110268716A1 (en) Methods for the enrichment of viable foxp3+ cells and uses thereof
JP2006166918A (ja) 造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法
US20150353897A1 (en) Method of generating multilineage potential cells
JP3917652B2 (ja) 造血促進細胞及びその使用
WO2018039810A1 (en) Provision of a therapeutically active cell product
EP3060653B1 (en) Method for reducing the inflammatory activity of a stem cell transplant and use thereof
JP2005505261A (ja) 樹状細胞単離法
JP6706836B2 (ja) 単核球培養用無血清培地
Gasner Characterizing the Effects of First Trimester Human Umbilical Cord Perivascular Cell (FTM HUCPVC) Treatment on the Lungs Using an α-α-PD-1/α-CTLA-4 Combination Immunotherapy Mouse Model

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20130507